Streetbeat News

Stock Prices

FXI

NVO

China's Medical Products Authority has approved Novo Nordisk's Type-2 diabetes treatment for entry into the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:57 pm

NVO

Correction issued for Novo Nordisk's ticker symbol, which is 'NVO'.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:56 pm

CG

SPY

David Rubenstein, Co-Founder of Carlyle Group, stated that the Federal Reserve is unlikely to cut interest rates before the upcoming elections. He also mentioned that the U.S. economy is performing well and is expected to grow by 2.5% this year.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:56 pm

AIQ

AVEM

BABA

Alibaba Cloud has introduced an AI programmer powered by its self-developed large language model to speed up app development. This innovation aims to reduce development time significantly, though it has received mixed reactions from human programmers. Alibaba's stock has faced challenges, losing 14% in the last year, but analysts predict a potential upside. Investors can gain exposure to Alibaba through ETFs like AVEM and AIQ.

Portfolio Pulse from Anusuya Lahiri

June 24, 2024 | 12:54 pm

ANIX

Anixa Biosciences has treated the sixth patient in its ongoing Phase 1 clinical trial of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for ovarian cancer. This marks a significant milestone in the development of their innovative cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:46 pm

SPY

Federal Reserve's Goolsbee emphasized that political considerations will not influence the Fed's monetary policy decisions.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:46 pm

SPY

Federal Reserve's Goolsbee refrains from commenting on the state of government finances, as reported by CNBC.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:45 pm

PRGS

Top Wall Street analysts have updated their expectations for Progress Software Corporation (NASDAQ:PRGS) ahead of its Q2 earnings release. Analysts predict earnings of $0.95 per share, down from $1.06 last year, and revenue of $168.42 million. Recent analyst ratings include Overweight, Outperform, Neutral, and Hold, with price targets ranging from $62 to $66.

Portfolio Pulse from Avi Kapoor

June 24, 2024 | 12:44 pm

BABA

JD

PDD

TCEHY

Chinese tech workers are facing intense pressure and overtime demands amid slow company growth and layoffs. JD.com founder Richard Liu warned employees against prioritizing work-life balance, indicating a push to eliminate underperforming IT engineers. Companies like Pinduoduo are being seen as models for rigorous work hours. Alibaba and Tencent have also laid off thousands of staff since 2021.

Portfolio Pulse from Benzinga Neuro

June 24, 2024 | 12:41 pm

VERU

Veru presented Phase 2 and 3 data for Enobosarm at the ADA Scientific Sessions, showing it is well-tolerated with an adverse event profile comparable to placebo. The drug is effective in reducing fat and preserving lean mass in older adults and cancer patients.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:39 pm